Clinical Scenario: Treating Late-Line Relapsed Multiple Myeloma

The panel provides key takeaways on the most impactful innovations shaping the future of multiple myeloma treatment.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Patients with relapsed/refractory multiple myeloma who also had a lower tumor burden were more likely to derive deeper responses to idecabtagene vicleucel.

Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

These data may support belantamab mafodotin, bortezomib, and dexamethasone as a new standard of care for patients with relapsed/refractory multiple myeloma.

Findings from this safety run-in cohort of teclistamab, daratumumab, and lenalidomide in newly diagnosed multiple myeloma will steer how randomization of the MajesTEC-7 trial will commence.